H. Res. 507 is a nonbinding House resolution that expresses support for designating June 10 as “FSGS Awareness Day.” The text collects medical and epidemiological findings about focal segmental glomerulosclerosis (FSGS), notes the costs and clinical burden of the condition, highlights genetic risks concentrated in people of African ancestry, and applauds advocacy and fundraising efforts.
Although it creates no new federal programs or funding, the resolution matters because it provides an evidentiary record that advocates can cite when pressing agencies, funders, and research partners for increased attention, earlier diagnosis, and access to emerging therapies. For stakeholders involved in clinical trials, community outreach, or transplant care, the resolution amplifies public visibility of a high-burden rare kidney disease and the inequities that accompany it.
At a Glance
What It Does
The resolution formally supports declaring June 10 as a day to raise awareness about FSGS, compiles findings about prevalence, clinical course, costs, and recurrence after transplant, and recognizes advocacy groups and fundraising events. It contains 'whereas' clauses summarizing data and three resolving clauses that express support, applaud advocates, and recognize commitment.
Who It Affects
Directly affected groups include people living with FSGS and their families, nephrology clinicians and transplant centers, patient advocacy organizations such as NephCure, researchers running FSGS trials, and public-health communicators targeting underserved communities. The bill has no regulatory reach over insurers or providers.
Why It Matters
By formalizing an awareness day and recording disease facts in the congressional record, the resolution can be used as a tool for outreach, fundraising, and trial recruitment, and it elevates discussion of APOL1-related risk and racial disparities—potentially shaping future policy proposals and research priorities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 507 is a House resolution offered to designate June 10 as “FSGS Awareness Day.” The text opens with a series of findings—short “whereas” clauses—that summarize scientific and epidemiological data about focal segmental glomerulosclerosis.
Those clauses note the relationship between FSGS and chronic kidney disease, describe the scarring process that defines FSGS, and emphasize the disease’s potential to progress to end-stage kidney disease requiring dialysis or transplant.
The resolution cites several consequential data points: roughly half of patients with FSGS will need dialysis or a transplant within five to ten years of diagnosis; recurrence after transplant can occur frequently and quickly; rare kidney-disease patients make up a small share of chronic kidney disease cases but a disproportionate share of kidney failure; and annual direct medical costs related to FSGS are large, cited at about $2 billion. The text also flags the long diagnostic odyssey for many patients and a shortage of nephrologists who specialize in rare kidney disorders.A prominent element of the preamble is the mention of APOL1 gene variants, which the resolution links to elevated risk in people of African ancestry and to observed racial disparities in disease burden.
The bill also highlights ongoing clinical trials and the prospect of near-term FDA-approved therapies, plus grassroots fundraising efforts such as the Tampa Pig Jig. The final clauses do not mandate actions or appropriate funds; instead, they express congressional support for the awareness day, applaud advocacy and research efforts, and recognize the commitment of families and professionals working on FSGS.
The Five Things You Need to Know
The resolution designates June 10 as “FSGS Awareness Day” and records supporting findings in the congressional record.
H. Res. 507 is ceremonial and nonbinding: it expresses support and recognition but does not create programs, appropriations, or regulatory obligations.
The text cites a clinical statistic that about 50 percent of patients with FSGS require dialysis or a kidney transplant within 5–10 years of diagnosis.
The bill highlights APOL1 genetic variants as a driver of disproportionate FSGS risk in individuals of African ancestry and notes recurrence risks after transplant of up to 50 percent (with higher risk for subsequent grafts).
The resolution names advocacy and fundraising efforts (including the Tampa Pig Jig) and points to ongoing clinical trials and efforts to validate proteinuria as an outcome that could support future approvals.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Assembles the evidentiary basis for designation
This section compiles clinical and epidemiological findings—prevalence of chronic kidney disease, FSGS as a cause of glomerulonephritis, progression to kidney failure, recurrence after transplant, cost estimates, diagnostic delays, and racial disparities tied to APOL1. Practically, including these facts in 'whereas' language gives advocates a concise, cited set of talking points they can use with agencies, funders, and the media; it also signals which data Congress considers important when thinking about disease burden.
Spotlights APOL1 and racial inequities
The bill explicitly links high-risk APOL1 variants to increased FSGS risk in people of African ancestry and frames FSGS as contributing to the disproportionate burden of kidney disease in Black communities. That emphasis can catalyze policy conversations about targeted screening, research on genetic mechanisms, and culturally tailored outreach—but it also raises questions about genetic testing, privacy, and how to translate risk knowledge into equitable care.
Frames urgency around diagnostic delays, costs, and trials
By calling out the multi-billion-dollar estimate of direct medical costs, the long average diagnostic odyssey (5–7 years), and active clinical trials, the resolution creates a narrative of both high burden and near-term opportunity. Stakeholders can point to these findings when seeking research dollars or pilot programs to reduce diagnostic delay; however, the clauses stop short of prescribing specific solutions or funding mechanisms.
Declares the awareness day and recognizes stakeholders
The operative text contains three short clauses: it (1) expresses support for the designation of June 10 as FSGS Awareness Day, (2) applauds advocates and organizations that promote awareness and research, and (3) recognizes the commitment of families, researchers, clinicians, and industry. Because these are expressions of sentiment rather than commands, they impose no legal obligations but serve as a public record of congressional support that groups can use for outreach and fundraising.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with FSGS and their families — the designation raises public visibility, which can ease patient recruitment for trials and increase philanthropic and community support.
- Patient advocacy organizations (e.g., NephCure) — the congressional record gives these groups a congressional citation to bolster awareness campaigns and fundraising appeals.
- Researchers and trial sponsors — heightened public awareness may accelerate trial enrollment and attract investigator attention to validating biomarkers such as proteinuria.
- Transplant centers and nephrology clinics — increased awareness can support earlier referrals, highlight the need for specialist capacity, and justify pilot programs to reduce diagnostic delay.
- Public-health communicators serving Black and other disproportionately affected communities — the resolution's focus on APOL1 supports targeted education and outreach planning.
Who Bears the Cost
- Congressional and committee staff — minor administrative and communication work to hold events or issue materials referencing the resolution; no new appropriations are required but staff time is necessary.
- State and local patient organizations — advocates may be expected to lead events tied to the awareness day, incurring outreach and event costs.
- Healthcare providers and clinics — if the awareness day drives demand for specialist visits or genetic testing, clinics may face capacity pressures and uncompensated coordination costs.
- Patients undergoing genetic testing — the spotlight on APOL1 could increase demand for testing, which may carry out-of-pocket costs and follow-on counseling needs if not covered by insurers.
- Research funders and sponsors — raising expectations for near-term therapies may increase pressure to fund additional trials or translational studies; that shifts financial priorities among public and private funders.
Key Issues
The Core Tension
The central tension is symbolic recognition versus substantive change: the resolution raises visibility for a high-burden, racially disparate disease—but it makes no binding commitments of funding, expanded specialist capacity, or genetic-data protections; highlighting APOL1-driven risk may accelerate targeted action but also risks amplifying privacy, access, and cost problems unless paired with concrete policy measures.
The resolution performs a clear symbolic function: it places facts about FSGS and APOL1-related disparities into the congressional record and designates a day for awareness. The trade-off is that symbolic recognition does not guarantee resources, system changes, or timelines for improved access to specialists or therapies.
Stakeholders should therefore treat the resolution as a tool for advocacy rather than a policy lever that changes coverage, research funding, or transplant practice by itself.
Highlighting APOL1 variants helps focus attention on an important driver of inequity, but it raises implementation questions. Promoting genetic awareness without a parallel framework for counseling, insurance coverage protections, and equitable access risks creating new administrative burdens for clinicians and financial burdens for patients.
There are also measurement issues: the bill cites cost and epidemiological estimates that come from specific studies and registries; different datasets or methodologies could produce materially different estimates of burden or recurrence rates. Finally, recurrent FSGS after transplant—presented in the resolution as a clinical challenge—has complex implications for transplant allocation policies and post-transplant management that this resolution does not address.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.